Chromogranin A
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non Functioning Pancreatic Endocrine Tumor
Conditions
Non Functioning Pancreatic Endocrine Tumor
Trial Timeline
Jun 1, 2012 → May 1, 2017
NCT ID
NCT02759718About Chromogranin A
Chromogranin A is a approved stage product being developed by Novartis for Non Functioning Pancreatic Endocrine Tumor. The current trial status is unknown. This product is registered under clinical trial identifier NCT02759718. Target conditions include Non Functioning Pancreatic Endocrine Tumor.
What happened to similar drugs?
0 of 1 similar drugs in Non Functioning Pancreatic Endocrine Tumor were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02759718 | Approved | UNKNOWN |
Competing Products
2 competing products in Non Functioning Pancreatic Endocrine Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pasireotide LAR | Novartis | Phase 2 | 35 |
| lanreotide (Autogel formulation) | Ipsen | Phase 3 | 37 |